Pharmaceutical & Life Sciences (CLE)

The Highs and Lows of Psychedelic Therapy: Navigating Legal Complexities


In recent years, psychedelics have been gaining popularity when it comes to treating an array of mental health issues. With its promising medical and therapeutic benefits, psychedelic-assisted psychotherapy (PAP) is generating significant interest among policymakers, medical professionals, and the public. As it provides an alternative treatment for refractory mental health concerns, several cities in the U.S are starting to decriminalize some psychedelics.

The Hatch-Waxman and IPR Strategy in Light of Recent Case Decisions: Addressing Emerging Issues


Inter partes review (IPR) proceedings have been an attractive ground for drug companies seeking to challenge the patentability of pharmaceutical products. The IPR allows challengers to maximize the streamlined process of the Patent Trial and Appeal Board (PTAB) while also taking advantage of the benefits provided by the Hatch-Waxman Act. Given this backdrop, the number of challenges utilizing the IPR process is predicted to continuously climb this year and beyond.

Food and Drug Regulatory Trends and Developments: Navigating Implications for the Year Ahead


The COVID-19 pandemic has resulted in a major shift in FDA regulatory and enforcement priorities and has had a drastic impact on the broader regulatory landscape. At the end of 2019, the agency was focused, among other issues, on opioids, youth vaping, food safety, compounding and overhauling the regulatory framework for dietary supplements. Today, FDA is focused on helping industry bring to market drugs, devices and vaccines critical to fighting the pandemic. Its enforcement efforts are focused on those who peddle false cures or distribute counterfeit or otherwise poor quality products. The world has changed, and with it the regulatory environment.

Biosimilars and the BPCIA: Exploring Trends, Developments, and Critical Issues


As the biosimilar industry continues to grow, significant legal developments and trends also continue to emerge and pose challenges to market participants. Questions currently hounding the future of the Biologics Price Competition and Innovation Act (BPCIA) litigation and regulatory pathway include the newly introduced Biologic Patent Transparency Act, the ongoing debates on the constitutionality of the Affordable Care Act (ACA), and the potential unavailability of inter partes and post-grant review proceedings for biosimilar manufacturers.

Go to Top